Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.

ACS sensors - 23 Mar 2018

Rodda Andrew E, Parker Bradyn J, Spencer Andrew, Corrie Simon R

Abstract excerpt

Liquid biopsies that analyze circulating tumor DNA (ctDNA) hold great promise in the guidance of clinical treatment for various cancers. However, the innate characteristics of ctDNA make it a difficult target: ctDNA is highly fragmented, and found at very low concentrations, both in absolute terms and relative to wildtype species. Clinically relevant target sequences often differ from the wildtype species by a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Liquid Biopsy

Share to Lung Cancer Treatments and Mutations

Share to Mutation

Share to Single-cell and spatial transcriptomics

Source

Identifiers

PMID: 29441780
DOI: 10.1021/acssensors.7b00953

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.PMID 29441780Read ↗

The feasibility of using mutation detection in ctDNA to assess tumor dynamics.Semantic proximity Read ↗

Circulating tumor DNA: current challenges for clinical utility.Semantic proximity Read ↗

Genetic profiling of cancer with circulating tumor DNA analysis.Semantic proximity Read ↗

Revolution of Circulating Tumor DNA: From Bench Innovations to Bedside ImplementationsSemantic proximity Read ↗

Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.Semantic proximity Read ↗

Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?Semantic proximity Read ↗

Decoding the Dynamics of Circulating Tumor DNA in Liquid BiopsiesSemantic proximity Read ↗

Toward liquid biopsies in cancer treatment: application of circulating tumor DNASemantic proximity Read ↗

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyondSemantic proximity Read ↗

Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNASemantic proximity Read ↗

Genomics and Epigenomics Approaches for the Quantification of Circulating Tumor DNA in Liquid Biopsy: Relevance of a Multimodal StrategySemantic proximity Read ↗

Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.